Senior Researcher
Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy, Italy
I am a Postdoctoral Fellow with 12 years laboratory experience in the field of cancer nanotechnology and pharmacology. My focus is the translational research in the field of sarcoma tumors and nanomedicine. My publication track record includes 70 papers related to sarcoma translational reseach and cancer nanothecnology (of which 16 first-authors articles, 5 last author and 1 book) in international peer-reviewed journals. I’m Guest Editor and editorial board member in Frontiers in Oncology and Pharmacology, Biomedicines, Vaccines and BioMed Research International. I'm referee for grants application for the National Science Center, Poland. I'm currently holding the position of referent of Translational Research into Osteoncology and Rare Tumors Center at IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori" for pharmacology, nanotechnology and sarcoma research platform. In 2014 I spent 1 year in the Houston Methodist Hospital (Prof. Ennio Tasciotti lab) as a Visiting Postdoctoral fellow where I worked on in vivo projects on the development of innovative nanosystems for the treatment of solid tumors. Moreover I was visiting researcher for 1 month in 2017 at National Cancer Institute (CRO) Aviano (Prof. Roberta Maestro lab) enriching my scientific knowledge and technical expertise in this research field. In 2019 I was visiting researcher for 1 month at Centre Léon Bérard Lyon (Prof. Jean-Yves Blay lab) to improve my skills in the establishment techniques of preclinical models for genomic and pharmacological profiling of sarcomas. Moreover in 2019 I represented Italian Oncology and Biothecnology Research at BioJapan and Regenerative Medicine Japan 2019 in Yokohama where I established with my Unit Director Dr. Toni Ibrahim a research collaboration with Prof. Tadashi Kondo of the National Cancer Center Reseach Institute of Tokyo for the genomic and pharmacological profiling of sarcoma patients.
